MarketCap
Facebook
X
Telegram
Cardiff Oncology Total Shareholders Equity | CRDF
Annual Total Shareholders Equity Cardiff Oncology
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 45.4 M | 82.9 M | 69.7 M | 106 M | 140 M | 128 M | 7.31 M | 10.1 M | 6.51 M | 19.8 M | 48.7 M | 8.35 M | 20.4 M | 2.17 M | -4.23 M | -5 M | -3.79 M | -4.05 M | -1.65 M | 3.48 M | 3.19 M | -1.58 M | -1.2 M | -719 K | -240 K | 27.2 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 140 M | -5 M | 26.2 M |
Quarterly Total Shareholders Equity Cardiff Oncology
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 82.9 M | 34.7 M | 69.7 M | 48.8 M | 58.6 M | 70.9 M | 82.9 M | 49.4 M | 52.4 M | 60.9 M | 69.7 M | 77.8 M | 86.6 M | 96.5 M | 106 M | 113 M | 120 M | 130 M | 140 M | 134 M | 139 M | 125 M | 128 M | 128 M | 128 M | 128 M | 7.31 M | 7.31 M | 7.31 M | 7.31 M | 10.1 M | 10.1 M | 10.1 M | 10.1 M | 6.51 M | 6.51 M | 6.51 M | 6.51 M | 19.8 M | 19.8 M | 19.8 M | 19.8 M | 48.7 M | 48.7 M | 48.7 M | 48.7 M | 8.35 M | 8.35 M | 8.35 M | 8.35 M | 20.4 M | 20.4 M | 20.4 M | 20.4 M | 2.17 M | 2.17 M | 2.17 M | 2.17 M | -4.23 M | -4.23 M | -4.23 M | -4.23 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 140 M | -4.23 M | 47.4 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AnaptysBio
ANAB
|
10.6 M | $ 51.0 | 1.83 % | $ 1.48 B |  USA |
 |
Allakos
ALLK
|
78.8 M | - | - | $ 28.6 M | USA |
 |
Black Diamond Therapeutics
BDTX
|
112 M | $ 1.88 | 0.53 % | $ 107 M | USA |
 |
Clovis Oncology
CLVS
|
-279 M | - | -7.23 % | $ 13 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
112 M | - | - | $ 401 M | USA |
 |
Evelo Biosciences
EVLO
|
-4.99 M | - | -14.46 % | $ 27.9 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
6.09 B | $ 60.26 | 0.06 % | $ 11.6 B | USA |
 |
BioNTech SE
BNTX
|
19.2 B | $ 98.52 | 0.24 % | $ 23.8 B |  Germany |
 |
Can-Fite BioPharma Ltd.
CANF
|
5.59 M | $ 2.17 | 0.46 % | $ 3.57 M |  Israel |
 |
Freeline Therapeutics Holdings plc
FRLN
|
52.4 M | - | - | $ 384 M |  Britain |
 |
Genocea Biosciences
GNCA
|
27.1 M | - | -15.0 % | $ 3.04 M | USA |
 |
Catalyst Biosciences
CBIO
|
106 M | $ 13.99 | 0.84 % | $ 1.25 B | USA |
 |
C4 Therapeutics
CCCC
|
257 M | $ 2.98 | 0.3 % | $ 247 M | USA |
 |
Codexis
CDXS
|
50.5 M | $ 1.32 | 1.09 % | $ 115 M | USA |
 |
Amryt Pharma plc
AMYT
|
357 M | - | - | $ 621 M | Britain |
 |
Cerus Corporation
CERS
|
64.2 M | $ 2.62 | 0.38 % | $ 499 M | USA |
 |
G1 Therapeutics
GTHX
|
35.4 M | - | - | $ 370 M | USA |
 |
Coherus BioSciences
CHRS
|
61 M | $ 1.13 | 0.43 % | $ 132 M | USA |
 |
Celldex Therapeutics
CLDX
|
527 M | $ 31.1 | 1.16 % | $ 2.07 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
6.08 M | $ 4.25 | 3.16 % | $ 51.9 M | Israel |
 |
Cellectar Biosciences
CLRB
|
8.54 M | $ 1.8 | 0.72 % | $ 4.69 M | USA |
 |
AbbVie
ABBV
|
-3.27 B | $ 264.34 | 0.09 % | $ 468 B | USA |
 |
Humanigen
HGEN
|
-46.8 M | - | -81.12 % | $ 4.28 M | USA |
 |
Cocrystal Pharma
COCP
|
6.33 M | $ 1.17 | 1.74 % | $ 13.2 M | USA |
 |
AbCellera Biologics
ABCL
|
967 M | $ 12.7 | 0.4 % | $ 3.79 B |  Canada |
 |
Abeona Therapeutics
ABEO
|
159 M | $ 5.4 | 2.65 % | $ 286 M | USA |
 |
Collegium Pharmaceutical
COLL
|
302 M | $ 22.53 | 0.2 % | $ 713 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
648 M | $ 116.1 | 4.93 % | $ 12.1 B | USA |
 |
IGM Biosciences
IGMS
|
48.2 M | - | - | $ 76.9 M | USA |
 |
IMV
IMV
|
-6.6 M | - | - | $ 13.1 M | Canada |
 |
Kinnate Biopharma
KNTE
|
159 M | - | - | $ 123 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
69.5 M | - | - | $ 231 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
148 M | $ 7.14 | 0.19 % | $ 95.1 M | USA |
 |
Karuna Therapeutics
KRTX
|
1.25 B | - | - | $ 12.2 B | USA |
 |
Curis
CRIS
|
5.46 M | $ 0.83 | 1.1 % | $ 10.9 M | USA |
 |
CorMedix
CRMD
|
405 M | $ 7.85 | 1.03 % | $ 565 K | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
992 M | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
1.92 B | $ 54.23 | 0.23 % | $ 4.88 B |  Schweiz |
|
Champions Oncology
CSBR
|
3.94 M | $ 4.9 | 0.1 % | $ 67.8 M | USA |
 |
Chimerix
CMRX
|
122 M | - | - | $ 756 M | USA |
 |
Corvus Pharmaceuticals
CRVS
|
61.2 M | $ 11.62 | 8.21 % | $ 918 M | USA |
 |
Cue Biopharma
CUE
|
26.4 M | $ 31.41 | 1.45 % | $ 2.98 B | USA |
 |
CEL-SCI Corporation
CVM
|
16 M | $ 1.67 | 2.38 % | $ 13.4 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
76.6 M | $ 4.85 | 0.2 % | $ 929 M | Canada |
 |
Cytokinetics, Incorporated
CYTK
|
-660 M | $ 64.66 | 0.17 % | $ 7.77 M | USA |
 |
Daré Bioscience
DARE
|
2.84 M | $ 0.78 | 4.73 % | $ 8.72 M | USA |
 |
Adagene
ADAG
|
35.3 M | $ 2.93 | 2.86 % | $ 173 M |  China |
 |
DiaMedica Therapeutics
DMAC
|
56.1 M | $ 7.94 | 1.4 % | $ 373 M | USA |